Born from interdisciplinary research at the intersection of oncology, immunology, and engineering, Avigen brings together deep biological insight with world-class microfluidic innovation.

We capture the strength and quality of immune–cancer cell interactions to unlock the full potential of your cell therapies. By enabling high-throughput, label-free selection of the most potent immune cells — while preserving viability — we are setting a new standard for immune cell discovery and validation.

Avigen bridges the gap between in-vitro and in-vivo results — enabling biotech and pharma teams to translate cell therapy R&D into the life-changing therapies it promises, faster and with greater confidence.